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Summary 
Porphyrias are uncommon inherited diseases of haem biosynthesis for which the diagnosis and treatment varies in 
individual countries. Despite the existence of guidelines recommended by porphyria experts concerning the diagnosis 
and management of the acute porphyrias, and of specialist centres in most European countries, many clinicians still do 
not apply these guidelines. The European Porphyia Initiative (EPI) network was formed in 2001 in order to compare 
experience among countries to attempt to develop a common approach to the management of the porphyrias, 
particularly concerning recommendation of safe and unsafe drugs, and to facilitate international collaborative clinical 
and biological research.  
The main achievements of EPI during this period have been: 
• Drafting and agreeing to consensus protocols for the diagnosis and management of acute hepatic porphyrias 
• Creation of a multilingual website, particularly focusing on guidelines for common prescribing problems in 
acute porphyria and on providing information for patients that is now available in 10 languages: 
www.porphyria-europe.org.  
EPI’s current objectives are to develop the EPI platform, expand to new countries, extend to non-acute porphyrias and 
design European research and clinical trials in porphyria. The project will focus on: 
1. Setting up a European laboratory external quality assurance scheme (EQAS) for biochemical and molecular 
investigations and their interpretation 
2. Establishing a consensus drug list in collaboration with the Nordic porphyria network 
3. Improving patient counseling 
4. Developing large multi-centre, multi-national research projects. Due to the rarity of the porphyrias, it would be 
very difficult for any one country to provide this data with a sufficient number of patients and within a 
reasonable timescale.  
The progress achieved will facilitate improvements in the treatment and development of new therapeutic strategies. It 
will set a pattern for establishing, and subsequently harmonising, between countries best clinical practice for a rare but 
important group of diseases, and will help to develop the optimal therapy and ensure its cost effectiveness. 
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Introduction 
 
The porphyrias are uncommon inherited 
metabolic disorders of haem biosynthesis in which 
specific patterns of overproduction of haem precursors 
are associated with characteristic clinical features. Each 
type of porphyria is the result of a specific decrease in the 
activity of one of the enzymes of haem biosynthesis. 
The porphyrias are inherited by a dominant 
autosomal mechanism, except in the cases of congenital 
erythropoietic porphyria and ALA-D deficiency (both 
extremely rare), which are inherited by a recessive 
autosomal mechanism. Porphyrias are classified as 
erythropoietic or hepatic in type, depending on the 
primary organ in which excess production of porphyrins 
ortheir  precursors takes place. 
Acute attacks occur in 4 of the porphyrias (acute 
intermittent porphyria (AIP), hereditary coproporphyria 
(HCP), variegate porphyria (VP) and ALA-D deficiency); 
their diagnosis and management have been extensively 
reviewed (Anderson et al. Scriver, eighth edition, 
Deybach 2004). 
The attacks consist of acute abdominal pain with 
vomiting and constipation, sometimes associated with 
neuro-psychiatric manifestations and may be followed by 
prolonged disability or end fatally.  
The diagnosis of an acute attack of porphyria 
requires demonstration of increased urinary excretion of 
the haem precursor, porphobilinogen (PBG). Further 
investigation is needed to identify the type of porphyria, 
but this should not be allowed to delay treatment. 
Specific treatment using intravenous haem 
should be started as soon as the diagnosis is established 
unless the attack is mild and clearly resolving. Any drugs 
or other potential provoking agents should be withdrawn. 
Care should be taken to avoid the risk of hyponatraemic 
seizures fromthe  inappropriate use of intravenous fluids. 
Family screening to identify those with the latent 
disease is essential for management of the autosomal 
dominant porphyrias. Patients and asymptomatic 
individuals who have inherited an acute porphyria must 
receive appropriate counselling, particularly about how to 
minimise the risk of an acute attack by avoiding drugs 
and other provoking factors. Despite the existence of a 
consensus on the diagnosis and management of the acute 
porphyrias, these guidelines are not applied, in practice, 
by all clinicians managing patients and their families; for 
example:  
Diagnosis may be made solely on the basis of a 
‘positive’ screening test for PBG and specific, 
quantitative measurement of urinary PBG omitted; or 
only urinary porphyrins may be measured 
(coproporphyrin excretion is often increased in acutely ill 
patients). 
Treatment is still based on high carbohydrate 
infusions which are no longer necessary when haem 
preparations are available.  
Experience suggests that haem treatment is safe 
during pregnancy (Elder et al. 2001); but this does not 
appear to be sufficiently widely known (Engelhardt et al. 
2004).  
Misinterpretation of information on drug lists; 
when prescribing, the benefit from using the drug of 
choice should always be assessed against the risk of 
provoking an acute attack and the likely consequence of 
not using it. Cases of women with breast cancer who have 
not been proposed optimum treatment for the cancer in 
order to avoid the risk of an acute attack have been 
reported (Deybach - unpublished)  
In almost every European country at least one 
porphyria diagnostic and advisory centre exists; however, 
these centres often do not collaborate and may even be in 
competition with each other. This approach goes against 
the progression of knowledge and the drive within 
Europe to centralize data on rare diseases.  
The EPI project was founded in an attempt to 
resolve these problems. 
 
European Porphyria Initiative (EPI) 
 
Objective 
The EPI network was formed in order to 
compare experience between countries, attempt to 
develop a common approach to the management of the 
porphyrias and to facilitate international collaborative 
clinical and biological research and development. 
 
Description of projects 
EPI set out to provide a forum for European co-
operation and exchange of information on the porphyrias 
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based on consensus by the participating members. This 
includes advice for clinicians, for example, on 
recommendations for common prescribing problems and 
on management, diagnosis and treatment of patients with 
porphyria and their families; EPI also provides 
information for patients. This platform will also facilitate 
international collaborative clinical and biological 
research. thus conforming to the requirements needed 
before applying to the various European and national 
research funding opportunities, for example the 
INSERM/AFM research network.   
 
Structure and management 
The EPI board was formed in 2001 and 
participants include 7 reference centres from France, 
Germany, Norway, Sweden, Switzerland and the UK; in 
order to facilitate EPI management, a new structure shall 
be put in place in 2005: 
- EPI Board: shall be comprised of a chairman, vice 
chairman, secretary, treasurer, working group managers 
and co-opted members. It shall be responsible for the 
general management of EPI and shall be the ultimate 
decision making body. 
- General Assembly: members shall be comprised of 
representatives from European porphyria diagnostic and 
advisory centres (specialist laboratories). 
- Working Groups: Working groups shall be appointed 
to address specific matters such as the classification of 
drugs and European laboratory quality assurance scheme. 
 
Results 
 
Since 2001 the EPI board held quarterly board 
meetings to discuss and agree consensus on the diagnosis, 
management and preventive treatment of the acute 
porphyrias. The resulting work has been published on the 
EPI website www.porphyria-europe.org. The website is 
divided into 4 main sections: information for people with 
Board 
General Assembly 
Working group Working group Working group 
 
 
Fig. 1. EPI structure and management in 2005 
 
 
Table 1. Information for people with acute porphyria 
 
1. WHAT IS ACUTE PORPHYRIA? 
2. WHAT IS AN ACUTE ATTACK OF PORPHYRIA? 
3. HOW MANY TYPES OF PORPHYRIA ARE THERE? 
4. HOW IS ACUTE PORPHYRIA INHERITED? 
5. WHAT IS THE RISK OF SYMPTOMS AMONG THOSE WHO HAVE INHERITED AN ACUTE PORPHYRIA GENE? 
6. HOW IS AN ATTACK OF ACUTE PORPHYRIA DIAGNOSED? 
7. WHEN IS THE BEST TIME TO BE TESTED FOR AN ACUTE PORPHYRIA? 
8. HOW ARE RELATIVES SCREENED FOR ACUTE PORPHYRIA? 
9. WHAT CAN I DO TO REDUCE THE RISK OF HAVING AN ACUTE ATTACK? 
10. SPECIAL PROBLEMS 
11. PARTICULAR ISSUES FOR WOMEN 
12. TREATMENT OF ACUTE ATTACKS 
13. SKIN PROBLEMS IN THE ACUTE PORPHYRIAS 
14. CONCLUSION 
15. PATIENT SUPPORT GROUPS 
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acute porphyria, information for health care specialists, 
drugs and porphyria, European diagnostic and advisory 
centres. 
 
Information for people with acute porphyria  
This section has been translated into 10 
languages: English, Dutch, French, German, Hebrew, 
Italian, Polish, Portuguese, Spanish and Turkish. The 
contents are listed in Table 1. 
 
Information for health care specialists 
This section provides information for health care 
specialists on the porphyrias, diagnosis, investigating the 
family, treatment and management of pain. Free access 
(no password) is provided in this section, thus allowing 
rapid access for individuals requiring an emergency 
consultation; nevertheless, the section carries a warning 
sign that the information is primarily written for 
healthcare specialists. 
 
Information on drugs 
Besides general principles on prescribing and a 
search engine for the safety of drugs, the originality of 
this section lies in the recommendations on common 
prescribing problems; 3 of these recommendations will 
now be described: 
 
 
Table 2. Recommendations for the use of hormonal contraception in the acute hepatic porphyrias 
 
 
All lists of drugs that should be avoided in the acute porphyrias (AIP, VP, HCP) include the contraceptive pill. It is there 
because it is known to provoke attacks of acute porphyria either alone or by interacting with other factors. This presents a 
problem for many women who have had an attack of porphyria or are related to someone who has. Not surprisingly, questions 
about the risk of using the contraceptive pill or other hormonal methods of contraception are some of the most common faced 
by doctors who look after patients with porphyria and their families. 
Though there is no doubt that the contraceptive pill, and particularly its progestrogen component, can provoke acute attacks, it 
is also well established that many women known to have inherited one of the acute porphyrias take the pill without any 
adverse effects. Unfortunately, there is no sure way of predicting how a woman with porphyria - whether or not she has 
previously had symptoms - will react.  
The only safe policy, therefore, is to use barrier methods of contraception and avoid the pill and other hormonal methods. 
However, this advice is not always acceptable particularly to women who have never had symptoms, some of whom may 
already be taking the pill when they are found to have porphyria. So here are some guidelines: 
Injectable (eg. Depo-Provera) and implanted hormone preparations are particularly dangerous – because they cannot be removed 
if an attack starts – and should never be used. 
Women who have had an attack of acute porphyria, even those who have been on the pill well before the attack started, should 
avoid all hormonal methods of contraception. If, after consultation with their doctor, they decide that they cannot do this, they 
must appreciate that they are running a real risk of becoming ill again. The same advice applies to women with variegate 
porphyria or hereditary coproporphyria who have only the skin disease caused by these conditions without the abdominal pain 
and other symptoms of acute porphyria. 
Women who have never had symptoms but come from a family with one of the acute porphyrias should be tested to see whether 
they are affected. If they are, they should follow the advice given above. This is particularly important for those in their teens and 
early twenties, the age group in which attacks often start. The risk of provoking an acute attack may be highest for women with 
acute intermittent porphyria, high urinary porphobilinogen (PBG) levels, or both of these together. If, after receiving full 
information about acute porphyria and discussion of the likely consequences with their doctor, they do decide to start on the 
contraceptive pill, they should have a urine test for PBG. If the level is high, the decision to go ahead with the pill should be 
reconsidered. Any woman in this group who starts on the pill should have her urine tested for PBG at regular intervals for several 
months. If PBG levels increase progressively, the pill should be stopped. She should also report immediately to her doctor if 
abdominal pain or any other potential indicator of acute porphyria develops. 
Women who have never had symptoms and have already been taking the pill for some time before they are found to be affected 
often wish to continue. However even in this group there is a risk that the pill may facilitate the provocation of an acute attack by 
another drug, alcohol, infection, stress or some other factor. Their urine should be tested for PBG and any decision to continue 
taken only after discussion with their doctor. 
The above advice applies only to the combined oral contraceptive pill that contains an oestrogen and a progestrogen and to oral 
and depot progestrogen-only preparations. Some intra-uterine devices (eg. Mirena) contain a progestrogen that has mainly a local 
action within the uterus and only enters the bloodstream in very small amounts. Experience to date suggests that this sort of device 
carries only a very low, if any, risk of provoking an acute attack. Oral emergency contraception preparations contain a high dose 
of progestrogen and are dangerous in porphyria; insertion of an intra-uterine device is therefore the safe alternative. 
All these remarks apply only to the acute porphyrias. The oestrogen component of the contraceptive pill may precipitate the skin 
disease, porphyria cutanea tarda, but acute attacks of porphyria do not occur in this condition. In addition, treatment is effective 
without withdrawing the pill, if this is impracticable. 
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Table 3. Recommendations for the use of local anaesthesia in the acute hepatic porphyrias  
 
The safety of local anaesthetic agents remains a controversial issue due to experimental evidence that some of the 
local anaesthetic agents are porphyrogenic in either animal models (e.g. lidocaine) or cell culture (e.g. lidocaine, 
mepivicaine, prilocaine, bupivacaine). However, despite this laboratory evidence, clinical experience has shown 
that most of these agents have been used in patients with acute porphyria without any notable adverse effect 
(HIFT 2000, MCNEILL 1990, BROWN 2002) 
General Points:  
These drugs are used in small doses, are metabolised slowly and there is no first pass effect. 
To date there are no case reports in the literature ascribing an acute attack to the use of local anaesthesia   
Dental Anaesthesia 
By far the most common requirement for local anaesthesia occurs when patients require dental treatment. In the 
majority of cases these procedures can be carried out under local anaesthetic.  
Suggestions: Bupivacaine (0.25-0.5 %) with adrenaline (1:200,000) 
Prilocaine (4 %) 
Regional Anaesthesia; Nerve blocks, epidural anaesthesia, spinal anaesthesia  
Several reports have documented the safe use of bupivacaine and procaine for epidural anaesthesia during labour. 
This has involved both extradural (bupivacaine, procaine) and spinal (bupivacaine) anaesthesia.  
Topical anaesthesia;  
There is little to suggest that local anaesthetic agents formulated for surface anaesthesia are associated with any 
significant risk. Examples of formulations and their uses include;  
Lidocaine; Gel (2 %) for use prior to venepuncture, minor skin procedures or urethral catheterisation; 
Spray (4-10 %) for use in procedures on the respiratory tract (intubation, bronchoschopy, ENT procedures)  
Amethocaine; Gel (4 %) for anaesthesia prior to venepuncture or minor skin procedures.  
Eye drops (0.5-1 %)  
Oxybuprocaine; Eye drops (0.4 %)  
Drugs which have been used safely as Local Anaesthetic Agents 
Amethocaine, Oxybuprocaine, Bupivicaine, Prilocaine, Lidocaine, Procaine, Mepivacaine, Tetracaine 
 
 
 
European diagnostic and advisory centres (porphyria 
specialist laboratories) 
As part if the EPI project, it was decided to set 
up a network of specialist European porphyria 
laboratories in which there will be collaboration and a 
quality assurance scheme (see Figure 2). As from 2005 
all laboratories are required to demonstrate that their 
services fulfil the following criteria: 
• Able to distinguish, using biochemical testing, 
between all types of porphyria 
• Able to offer specialist detailed interpretation 
of results with clinical advice on management 
• Participation in EPI-organised quality 
assurance schemes. Quality assurance 
schemes will be organized in 2005 and more 
information will be available early in 2005 
• An application form for specialist laboratories 
can be downloaded from the EPI website 
 
Future perspectives 
The core functions of EPI consist of updating 
and reviewing the website, developing a consensus list 
of safe and unsafe drugs and setting up an external 
quality assurance scheme.  
 
 
 
Fig. 2. EPI website list of partners in December 2004 
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Table 4. Recommendations in the management of convulsions and epilepsy in patients with acute porphyria 
 
Seizures may occur (a) as a manifestation of acute porphyria, where they may be secondary to the hyponatraemia that 
develops in up 35 % of acute attacks or (b) due to a cause unrelated to porphyria. Treatment firstly involves 
terminating the seizure and then assessing the likely cause and planning the most appropriate therapy. In the case of 
hyponatraemia this involves slow correction of the electrolyte imbalance by fluid restriction and isotonic or 
hypertonic saline where necessary.   
A major problem in the management of seizures is that many of the commonly used anticonvulsants can precipitate 
or worsen acute attacks. Therefore where a primary seizure disorder is suspected this should be fully investigated by 
an epilepsy expert to ensure that treatment is absolutely necessary.  
I. Acute seizure or status epilepticus during an acute attack 
Termination of an acute convulsion should be with an intravenous benzodiazepine such as lorazepam, diazepam or 
clonazepam. The choice of diazepam may be controversial but it is almost certainly safe as a single intravenous dose. 
Under no circumstances should phenytoin or phenobarbitone be used.  
Where benzodiazepine treatment fails, paraldehyde or magnesium sulphate should be considered.  
Where general anaesthesia is required propofol is the drug of choice.  
II. Epilepsy  
a) New diagnosis of epilepsy in patient known to have an acute porphyria 
Wherever possible an anticonvulsant should be chosen from the list of safe alternatives below. When control of 
epilepsy is particularly difficult or no safe alternative is effective, discussion with a recognised porphyria expert may 
help in the selection of an appropriate drug regime that minimises risk to the patient. Close biochemical monitoring 
by regular measurent of urine porphobilinogen is advisable under these circumstances.  
b) New diagnosis of acute porphyria in an epilepsy patient on anticonvulsants 
Where the patient is on an anticonvulsant that carries a particularly high risk (e.g. carbamazepine, phenytoin, 
phenobarbitone, primidone, ethosuximide) changing to a safer alternative is advisable. However, change of therapy 
may occasionally provoke either acute porphyria or epilepsy and the patient should always be informed of the risk 
and carefully monitored.  
In some cases the risk of changing anticonvulsant therapy, e.g. in a patient whose seizures are difficult to control, 
may outweigh that of inducing an acute attack. In these circumstances, the patient should be informed of the risk and 
advised to seek medical help should symptoms of acute porphyria develop. 
ANTI-EPILEPTIC DRUGS AVAILABLE 
(P; denotes porphyrogenic in cell culture/animal model, C; denotes drug known to cause acute attacks in patients) 
Use: Clobazam, Clonazapam7  Lorazepam8  Gabapentin1,2  Acetazolamide(Vigabatrin1) #Paraldehyde 
Use with Caution: Valproate4,6 Diazepam8 
Avoid (Evidence):  Carbamazepine5,6 (P,C) Phenytoin7 (P,C) Phenobarbitone (P,C) Primidone (P,C) Ethosuximide 
(P,C) Tigabine1,3 (P) Lamotrigine1 (P) (Felbamate1^)(P) Topiramate1,2 (P) Oxcarbazine (P) 
No data: Levetiracetam* 
# Vigabatrin is associated with the development of irreversible visual field defects and is very rarely prescribed in 
adults. Use should be supervised by a neurologist experienced in epilepsy management. 
^ Felbamate is associated with bone marrow suppression and would only be used with great caution. 
* Levetiracetam is not dependant on hepatic cytochrome P450 system elimination and does not induce hepatic 
enzymes. The main route of excretion of parent drug and metabolites is renal. 
In view of this it would be expected to be safe (HAHN 97, ZADRA 98, KRIJT 2001, MCGUIRE 1988, REYNOLDS 
1981, LARSON 1978, LAMBRECHT 1999) 
 
 
 
International collaboration to collect all available 
information on the porphyrniogenicity of drugs is 
necessary; The Nordic porphyria centres have set up a 
rigorous, comprehensive, high-tech database classifying 
drugs into 5 risk categories (not porphrinogenic, probably 
not porphyrinogenic, possibly porphyrinogenic, probably 
porphrinogenic, documented porphrinogenic). The 
manager of the Nordic group is also manager of the EPI 
drug working group whose objective is to draft and agree 
to/on a consensus drug list. 
The EPI platform will also focus on large multi-
centre, multi-national research projects looking at the 
association of porphyria and other chronic manifestations 
and identification of unusual variant forms of porphyria. 
This type of research is only possible with the large pool 
of patients available in the European population. 
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